Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03475186 | Testing Ramipril to Prevent Memory Loss in People With Glioblastoma | completed | Phase 2 | 75 | Wake Forest University Health SciencesOTHER | 2 | Mar 13, 2026 | clinicaltrials |
| NCT04044937 | Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms(UC-GlioFET) | completed | Phase 2 | 143 | Thomas HopeOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04716699 | Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma | completed | Phase 1 | 12 | University of California, DavisOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04391595 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | completed | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00026312 | Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | completed | Phase 3 | 1,449 | National Cancer Institute (NCI)NIH | 5 | Mar 5, 2026 | clinicaltrials |
| NCT05431348 | Effect of stRess and exeRcize on the Outcome After Chemo-Radiation(ERROR) | completed | — | 42 | Maastricht Radiation OncologyOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04343573 | Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02669173 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04268979 | Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator | completed | N/A | 296 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05938387 | Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma | completed | Phase 1 | 37 | CureVacINDUSTRY | 3 | Feb 18, 2026 | clinicaltrials |
| NCT03450850 | Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma | completed | N/A | 1 | Daniela A. BotaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03681028 | Feasibility of Individualized Therapy for Recurrent Glioblastoma | completed | Phase 1 | 30 | Jennifer ClarkeOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02909777 | Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04822688 | Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues | completed | — | 141 | Thomas Jefferson UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04173104 | PET and MRI Imaging of Brain Tumors Using [18F]PARPi | completed | Early Phase 1 | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03048240 | INtraoperative photoDYnamic Therapy of GliOblastoma(INDYGO) | completed | N/A | 10 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03361033 | Components of Social Functioning in Survivors of Pediatric Brain Tumors | completed | — | 80 | St. Jude Children's Research HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03703167 | Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT00336024 | Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma | completed | Phase 3 | 91 | Children's Oncology GroupNETWORK | 4 | Jan 23, 2026 | clinicaltrials |
| NCT01175356 | Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin | completed | Phase 1 | 99 | Children's Oncology GroupNETWORK | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT04134117 | Tisagenlecleucel In Primary CNS Lymphoma | completed | Phase 1 | 13 | Matthew J. Frigault, M.D.OTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT00085930 | Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma Patients(NESTLES) | completed | Phase 1 | 19 | Baylor College of MedicineOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06031194 | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | completed | — | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02617745 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid(GLIOPLAK) | completed | Phase 2 | 244 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05735171 | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence(SupraGlio-AI) | completed | N/A | 20 | Hospital del Rio HortegaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT01850888 | MIBG for Refractory Neuroblastoma and Pheochromocytoma | completed | N/A | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT04566185 | Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma(EVA DOPA) | completed | N/A | 14 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06451042 | FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)(FET-TREAT) | completed | — | 11 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03638167 | EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors | completed | Phase 1 | 11 | Seattle Children's HospitalOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05432375 | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | completed | Early Phase 1 | 10 | Mundipharma Research LimitedINDUSTRY | 2 | Dec 10, 2025 | clinicaltrials |
| NCT04391062 | Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma(DOSINDYGO) | completed | Phase 2 | 14 | University Hospital, LilleOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT02238899 | Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma | completed | — | 354 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04116658 | First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma(ROSALIE) | completed | Phase 1 / Phase 2 | 100 | EnteromeINDUSTRY | 4 | Nov 28, 2025 | clinicaltrials |
| NCT03224104 | Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.(STEAM) | completed | Phase 1 | 71 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Nov 26, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT01582269 | A Study in Recurrent Glioblastoma (GB) | completed | Phase 2 | 158 | Eli Lilly and CompanyINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Mar 16, 2026source: clinicaltrials